According to the research report titled ‘Asia Pacific Bioreactors Market Size By Technology, Cell, Molecule, End-use, Industry Analysis Report, Country Outlook, Application Potential, Competitive Market Share & Forecast, 2018 – 2025’, available with Market Study Report, Asia-Pacific bioreactors market is expected to surpass USD 470 million by the year 2025.
 

As per the report, surging investments in R&D by biopharmaceutical companies, growing demand for therapeutic vaccines, and increased pervasiveness of lifestyle diseases are major factors driving the Asia-Pacific bioreactors market growth. Advancements in technology pertaining to bioreactor processing, design, and material along with favorable government initiatives towards development of healthcare facilities are further facilitating the market expansion. Moreover, growing personalized medicine market will create lucrative growth avenues for bioreactors market in Asia-Pacific region. However, factors such as limited storage capacity and susceptibility to leaching may hinder the market growth. Strict government regulations regarding single-use bioreactors and large-scale disposal of plastic derivatives will restrain the APAC bioreactors market.
 

As per cell type, mammalian cells segment is expected to grow with a CAGR of 19.1% during 2018-2025. These cells are used in biopharmaceutical industry for numerous applications such as production of therapeutic glyco-proteins, cultivation of tissue cells for artificial organs, and production of monoclonal antibodies among others.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2506082/
 

In terms of molecule type, recombinant protein segment garnered USD 18.1 million in 2018 and is presumed to expand substantially during the estimated timeframe. Increasing application of recombinant proteins for treating rheumatic conditions and cancers is fueling the segmental growth.
 

Based on technology outlook, single-use bubble column segment is slated to witness a growth rate of 19.3% during 2018-2025. The technology offers low operating and maintenance cost, compactness, and high mass and heat transfer rates.
 

Citing the end-use landscape, Asia Pacific bioreactors market from biopharma manufacturers segment was wroth USD 47.3 million in 2018 and is poised to acquire commendable gains in the forthcoming years. Increasing development of new facilities in order to meet production needs along with dense presence of biopharmaceutical players in emerging economies are facilitating the business scenario in Asia-Pacific region.
 

Geographically, Japan held 28.7% market share in 2018 and is set to record a considerable growth rate in the subsequent years. Rising number of biopharmaceutical companies has led to development of innovative medications for patients. Furthermore, increasing collaboration activities between biopharmaceutical companies, venture capital firms, and academic institutions coupled with surging investments by public entities towards development of innovative drugs are augmenting the demand for bioreactors in Japan.
 

The prominent companies operating in Asia-Pacific bioreactors market are Thermo Fisher Scientific Inc., Solaris Biotech Solutions, Shanghai Bailun Biotechnology Co. Ltd., Sartorius Stedim Biotech Group, Pierre Guerin SAS, PBS Biotech Inc., Merck Group, GEA Group Aktiengesellschaft, GE Healthcare, Eppendorf AG, CESCO Bioengineering Co. LTd., Cellexus Ltd., and Applikon Biotechnology Inc.